Investors

  • 2021-07-12
    VOLUNTARY ANNOUNCEMENT ENTERING INTO STRATEGIC COMMERCIAL PARTNERSHIP WITH TENCENT
  • 2021-07-07
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED JUNE 30, 2021
  • 2021-07-05
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON LICENSING PARTNER SPERO THERAPEUTICS, INC. ENTERED INTO LICENSING AGREEMENT WITH PFIZER INC. FOR SPR206 IN EX-UNITED STATES AND EX-ASIA TERRITORIES
  • 2021-06-22
    GRANT OF SHARE AWARDS
  • 2021-06-07
    NEXT DAY DISCLOSURE RETURN
  • 2021-06-05
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED MAY 31, 2021
  • 2021-06-01
    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON TUESDAY, 1 JUNE 2021
  • 2021-05-20
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON CHINA NMPA GRANTING PRIORITY REVIEW FOR SACITUZUMAB GOVITECAN-HZIY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER
  • 2021-05-17
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON CHINA NMPA ACCEPTING BIOLOGICS LICENSE APPLICATION FOR SACITUZUMAB GOVITECAN-HZIY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER
  • 2021-05-07
    GRANT OF SHARE OPTIONS AND SHARE AWARDS
 Copyright Everest Medicines 2020  云顶药业(苏州)有限公司 苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers

沪公网安备 31010602006477号